New Zealand markets closed

Atai Life Sciences N.V. (ATAI)

NasdaqGM - NasdaqGM Real-time price. Currency in USD
Add to watchlist
1.3325+0.0025 (+0.19%)
As of 10:49AM EDT. Market open.
Full screen
Trade prices are not sourced from all markets
Previous close1.3300
Open1.3600
Bid1.3200 x 200
Ask1.3500 x 200
Day's range1.3241 - 1.4400
52-week range1.0250 - 2.8500
Volume473,309
Avg. volume1,375,541
Market cap223.068M
Beta (5Y monthly)0.83
PE ratio (TTM)N/A
EPS (TTM)-0.2100
Earnings date06 Aug 2024 - 13 Aug 2024
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est10.68
  • GlobeNewswire

    atai Life Sciences Announces Update on Beckley Psytech’s Phase 1/2a Trial of ELE-101 (IV Psilocin) for Major Depressive Disorder, with Initial Results from Phase 1 and First Patients Dosed in Phase 2a

    ELE-101 is a patent-protected, synthetic formulation of psilocin, designed to offer the therapeutic benefits of psilocybin in a more consistent, controllable, and shorter treatment paradigm of approximately two hours.The Phase 2a part of the study will evaluate the safety, tolerability, subjective effects, and efficacy of a single intravenous (IV) dose of ELE-101 in 6-12 participants with Major Depressive Disorder (MDD). Results are expected in H2 2024.The dose for Phase 2a was selected using pr

  • GlobeNewswire

    atai Life Sciences to Participate in the Jefferies 2024 Global Healthcare Conference

    NEW YORK and BERLIN, May 31, 2024 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai” or “Company”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, today announced that the Company’s management team will participate in the Jefferies Global Healthcare Conference being held from June 4-6, 2024. Details of the company’s participation: Format: Fireside ChatDate and Time: Thursday June 6 at 10:00 A.M. ETLocation: New YorkWebcast link

  • GlobeNewswire

    atai Life Sciences Strengthens Board with Appointment of Two New Independent Directors

    NEW YORK and BERLIN, May 23, 2024 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai” or “Company”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, today announced the appointment of Scott Braunstein, M.D., and Laurent Fischer, M.D., as independent directors of atai’s supervisory board (“Board”) subject to applicable legal requirements. Scott Braunstein, M.D., is the Chief Executive Officer (“CEO”) and Chairman of Marinus Pharma